PFE Pfizer Inc

   By Stephen Nakrosis 
 

The U.S. Food and Drug Administration on Wednesday approved Daurismo, a Pfizer Inc. (PFE) drug, for some patients with acute myeloid leukemia.

The approval is for Daurismo in combination with low-dose cytarabine, a type of chemotherapy, to treat newly-diagnosed acute myeloid leukemia in adults over 75 and others who have other health conditions or diseases that may preclude more intense chemotherapy.

The FDA said it granted this application Priority Review designation and also gave the Orphan Drug designation to Daurismo. The Orphan Drug Act grants special status to a drug or biological product to treat rare diseases and conditions upon request of a sponsor, the FDA said.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

November 21, 2018 13:34 ET (18:34 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.